TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05047861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket shield technique with autogenous dentin graft
Description: The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After the final preparation of the socket shield, Graft will be placed using autogenous dentin graft from the discarded palatal part of the tooth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket shield technique with alloplast graft
Description: The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After final preparation of socket shield, Graft will be placed Alloplast graft
Study: NCT03133247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: PD-L1
Study: NCT03348839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeLLY service
Description: Telesurveillance and therapeutic support
Study: NCT00676663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Exemestane 25 mg tablet orally once daily
Study: NCT00676663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exemestane
Description: Exemestane 25 mg tablet orally once daily
Study: NCT02037594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Adherence Support (Active Control)
Description: Standard of care information and instruction about PrEP adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Adherence Support (Active Control)
Description: Standard of care information and instruction about PrEP adherence.
Study: NCT02743182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Study: NCT02254629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Clostridium Butyricum
Description: probiotic:2 tablets/ times, 3 times / day for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Clostridium Butyricum
Description: probiotic:2 tablets/ times, 3 times / day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Clostridium Butyricum
Description: probiotic:2 tablets/ times, 3 times / day for 2 weeks
Study: NCT02480556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual seperation of the placenta
Description: manual separation of the placenta will be done immediately after fetal extraction \& cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative separation of placenta
Description: Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu \& uterus is massaged awaiting spontaneous placental separation
Study: NCT00253578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03152370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7046
Description: oral administration
Study: NCT03348839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeLLY service
Description: Telesurveillance and therapeutic support

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeLLY service
Description: Telesurveillance and therapeutic support

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeLLY service
Description: Telesurveillance and therapeutic support

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeLLY service
Description: Telesurveillance and therapeutic support
Study: NCT03785704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xinmailong Injection
Description: Xinmailong injection is extracted, separated, purified and refined from Periplaneta americana. It is the second class of new drugs and the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China) for the prevention and treatment of heart failure. Its main constituents include complex nucleoside bases and binding amino acids.
Study: NCT01002651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wheat bran extract
Description: soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wheat bran extract
Description: soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
Study: NCT00825188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone, amlodipine
Description: Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone, amlodipine
Description: Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: Eplerenone 25-50mg daily x 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: eplerenone 25- 50 mg daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: eplerenone 25- 50 mg daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 5-10mg daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 5-10mg daily for 8 weeks
Study: NCT02379169

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil & lutein
Description: Standardised sea buckthorn seed and pulp oil complemented with lutein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Triglycerides of medium chain fatty acids
Study: NCT03818750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Subjects review alcohol ads in different contexts (neutral context vs positive context such as parties and sport) and answer with buttons lever while being in the MRI to express their desire to consume alcohol or not.~Subjects will be exposed to 288 ads set up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test
Description: Questionnaire
Study: NCT00890747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02346461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ManNAc
Description: At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ManNAc
Description: At doses of 6 g twice daily (12 g per day).
Study: NCT03940729

Intervention type: DRUG
Group type: OTHER
Intervention: Chlorhexidine Topical
Description: In the Malmö needle exchange program, people who inject drugs (PWID) are repeatedly screened for S aureus colonization during one year. Those colonized will repeatedly shower with chlorhexidine during the following year. The infection frequency will be compared between the two periods.
Study: NCT02311114

Intervention type: OTHER
Intervention: In Depth interview
Description: In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.

Intervention type: OTHER
Intervention: In Depth interview
Description: In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.

Intervention type: OTHER
Intervention: In Depth interview
Description: In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.

Intervention type: OTHER
Intervention: In Depth interview
Description: In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.

Intervention type: OTHER
Intervention: Observational fieldwork
Description: Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.

Intervention type: OTHER
Intervention: Observational fieldwork
Description: Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.

Intervention type: OTHER
Intervention: Observational fieldwork
Description: Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.

Intervention type: OTHER
Intervention: Observational fieldwork
Description: Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.

Intervention type: OTHER
Intervention: Survey
Description: Surveys with participants will be conducted using validated survey tools.

Intervention type: OTHER
Intervention: Survey
Description: Surveys with participants will be conducted using validated survey tools.
Study: NCT00014079

Intervention type: GENETIC
Intervention: DNA stability analysis

Intervention type: GENETIC
Intervention: loss of heterozygosity analysis

Intervention type: GENETIC
Intervention: microsatellite instability analysis
Study: NCT02254629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laxative Polyethylene Glycol
Description: laxative：2000 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laxative Polyethylene Glycol
Description: laxative：2000 ml.
Study: NCT01016600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT01412411

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritionl Education
Description: to assess the change in behaviour

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron Supplementation along with Nturition Eductaion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple micronutrient fortification plus Nutrition Education
Study: NCT01398540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IXIARO
Description: 2 immunizations (0,5ml) with a 28 day interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IXIARO
Description: 2 immunizations (0,5ml) with a 28 day interval
Study: NCT03152370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7046
Description: oral administration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long Course Chemoradiotherapy (LCRT)
Description: pelvic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short Course Radiotherapy (SCRT)
Description: pelvic radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid/5-FU/oxaliplatin (mFOLFOX-6)
Description: chemotherapy
Study: NCT03738943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Triphosphate
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Triphosphate
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Triphosphate
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Diphosphate
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Monophosphate
Description: See arm/group descriptions
Study: NCT01465594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral catheter after EERPE/ RALP
Description: transurethral catheter after EERPE/ RALP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral catheter after EERPE/ RALP
Description: transurethral catheter after EERPE/ RALP
Study: NCT03738943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uridine Triphosphate
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B 6
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B 6
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B 6
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxal 5'-Phosphate
Description: See arm/group descriptions
Study: NCT01465594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprapubic catheter after EERPE /RALP
Description: suprapubic catheter after EERPE /RALP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprapubic catheter after EERPE /RALP
Description: suprapubic catheter after EERPE /RALP
Study: NCT03738943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxal 5'-Phosphate
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxal 5'-Phosphate
Description: See arm/group descriptions
Study: NCT00585468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Myfortic 720 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Myfortic 720 mg orally twice daily
Study: NCT04107480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic trans-sphenoidal adenoma resection
Description: Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice.
Study: NCT01285180

Intervention type: DRUG
Intervention: Daxas
Description: 500 microgram, oral, once daily as add-on therapy to existing therapy
Study: NCT01205139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 7 days
Study: NCT04107480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine Agonists
Description: The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care.
Study: NCT03884621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHP Group
Description: The Enhanced post-discharge home-based care program (EHP) plus usual care
Study: NCT01205139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablet once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + TDF
Description: 150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + TMC278
Description: 150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25 mg tablet once daily for 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 11 days
Study: NCT01441622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AL539 (SRETT)
Description: recording data with AL539 (SRETT)
Study: NCT00957840

Intervention type: PROCEDURE
Group type: OTHER
Intervention: NIRS, aEEG, and CSF concentration of biomarkers
Description: NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
Study: NCT01557400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Oral powder for suspension
Study: NCT05716828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balint group activities
Description: A Balint group is a working form that focuses on the professional doctor-patient relationship. Participants in the Balint group completed Balint training for a period of at least three months, which included two lectures and 10 small group discussion sessions held once a month for one hour at a time (on Thursdays from 12 to 1 PM). Balint group is a closed group including one to two group leaders and six to twelve participants, with sessions lasting 60 to 90 minutes.
Study: NCT01446731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA transfected dendritic cell
Description: Autologous monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
Study: NCT03200925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jumping into Kangaroo Care - a video created by the Ohio Department of Health
Description: The video is 8 minutes and 52 seconds in length. The video discusses the benefits and logistics of Kangaroo Care from professional's perspectives and from new mother's perspectives.
Study: NCT03209154

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring
Description: Therapeutic drug monitoring will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home blood pressure monitoring
Description: Patients will perform home blood pressure monitoring at home.
Study: NCT04136522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional pancreaticoduodenectomy
Description: In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total mesopancreas excision including superior mesenteric artery first approach
Description: In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
Study: NCT03973346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk screening tool exposure
Description: Risk screening tool is available to providers
Study: NCT01010048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone,tamsulosin,propantheline Bromide and nifedipine
Description: clearance rate of stone
Study: NCT01016600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study: NCT00739752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Framed-Offered
Description: Subjects received information only and are offered the vaccine.
Study: NCT00676663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching entinostat tablet orally once per week